Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

被引:0
作者
Kian Huat Lim
Zhou Han
Hyun Yong Jeon
Jacob Kach
Enxuan Jing
Sebastien Weyn-Vanhentenryck
Mikaela Downs
Anna Corrionero
Raymond Oh
Juergen Scharner
Aditya Venkatesh
Sophina Ji
Gene Liau
Barry Ticho
Huw Nash
Isabel Aznarez
机构
[1] Stoke Therapeutics,
[2] Inc.,undefined
来源
Nature Communications | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
While most monogenic diseases are caused by loss or reduction of protein function, the need for technologies that can selectively increase levels of protein in native tissues remains. Here we demonstrate that antisense-mediated modulation of pre-mRNA splicing can increase endogenous expression of full-length protein by preventing naturally occurring non-productive alternative splicing and promoting generation of productive mRNA. Bioinformatics analysis of RNA sequencing data identifies non-productive splicing events in 7,757 protein-coding human genes, of which 1,246 are disease-associated. Antisense oligonucleotides targeting multiple types of non-productive splicing events lead to increases in productive mRNA and protein in a dose-dependent manner in vitro. Moreover, intracerebroventricular injection of two antisense oligonucleotides in wild-type mice leads to a dose-dependent increase in productive mRNA and protein in the brain. The targeting of natural non-productive alternative splicing to upregulate expression from wild-type or hypomorphic alleles provides a unique approach to treating genetic diseases.
引用
收藏
相关论文
共 89 条
[1]  
Prakash V(2016)Current progress in therapeutic gene editing for monogenic diseases Mol. Ther. 24 465-474
[2]  
Moore M(2017)Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery Orphanet. J. Rare Dis. 12 16-77
[3]  
Yáñez-Muñoz RJ(2018)Recent progress and considerations for AAV gene therapies targeting the central nervous system J. Neurodev. Disord. 10 eaau0629-70
[4]  
Chen B(2018)CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency Science 363 68-880
[5]  
Altman RB(2017)Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—an innate immune system standpoint Semin. Immunol. 34 57-33
[6]  
Lykken EA(2019)Treating disease at the RNA level with oligonucleotides New Engl. J. Med. 380 875-476
[7]  
Shyng C(2016)Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames Nat. Biotechnol. 34 1-64
[8]  
Edwards RJ(2015)Mechanisms and regulation of alternative pre-mRNA splicing Annu. Rev. Biochem. 84 470-393
[9]  
Rozenberg A(2008)Alternative isoform regulation in human tissue transcriptomes Nature 456 52-100
[10]  
Gray SJ(2004)An unappreciated role for RNA surveillance Genome Biol. 5 385-1078